Weight loss injections can support medically indicated weight management, but they can also cause side effects. With tirzepatide, digestive symptoms such as nausea, diarrhoea, constipation and vomiting are among the main concerns. Symptoms may be more noticeable during dose increases and can ease over time. Severe or persistent symptoms still need medical attention.
The term “weight loss injections” covers different prescription medicines, each with its own instructions and risk profile. This article focuses on tirzepatide, the active ingredient in Mounjaro, which is used for medically indicated weight management. The information should not be applied automatically to another medicine.
What side effects can weight loss injections cause?
Digestive symptoms
Tirzepatide can cause nausea, vomiting, diarrhoea, constipation, abdominal discomfort and indigestion. For someone starting treatment, the practical questions are how severe the symptoms are, whether they are improving and whether they interfere with eating or drinking.
The current EU product information describes nausea, vomiting and diarrhoea as more frequent during dose escalation, with their incidence decreasing over time. That pattern does not mean you should put up with persistent vomiting or significant pain. Report troublesome symptoms to the prescriber before any planned increase.
Smaller balanced meals and adequate fluids can help you manage digestive symptoms during treatment. Your clinician can adapt this advice to your circumstances. If you have been told to limit fluids because of another health condition, discuss an appropriate plan rather than following a general hydration target.
Other possible effects
Injection-site reactions, tiredness and dizziness can occur. Gallstones and gallbladder inflammation are also recognised risks. The patient leaflet lists additional possible effects, so tell your clinician about new symptoms even if they are not mentioned here.
Low blood sugar is a particular concern when tirzepatide is used with insulin or a sulphonylurea, a type of diabetes medicine. Your prescriber may need to review the wider diabetes treatment plan. Do not change those medicines yourself.
Which symptoms need medical help?
A symptom can be listed as a known side effect and still require treatment. Use its severity and impact to guide how urgently you seek advice.
- Severe, persistent abdominal pain, especially if it extends to the back: seek medical help immediately. This can indicate pancreatitis. Tirzepatide should be stopped if pancreatitis is suspected; tell the assessing clinician when you last took it and follow their instructions before any further dose.
- Repeated vomiting or an inability to keep fluids down: obtain prompt medical advice. Dehydration can affect kidney function.
- Possible low blood sugar: follow the response plan provided by your diabetes team and seek urgent help if symptoms are severe or do not resolve.
- Breathing difficulty, swelling of the lips, tongue or throat, or collapse: seek emergency assistance. In Germany, call 112.
Do not wait for your next routine appointment when symptoms are severe. Keep the medicine’s name, your current prescription and the date of the last injection available when contacting a healthcare professional.
How do weight loss injections work?
Tirzepatide acts on receptors for two hormones, GIP and GLP-1, which help regulate appetite and blood glucose. It can reduce appetite and food intake and also slows stomach emptying. It is given as a once-weekly injection under the skin.
The European Medicines Agency describes its use for weight management alongside a reduced-calorie diet and increased physical activity. It does not selectively dissolve fat in one body area, and it should not be confused with an injectable treatment intended for local contouring.
Dose increases follow the prescription schedule and depend on tolerability and treatment goals. Do not increase the dose to speed up weight loss or treat side effects as evidence that it is working better.
Who may be eligible for treatment?
Under the EU weight-management indication, tirzepatide is used in adults with an initial body mass index (BMI) of:
- 30 kg/m² or higher; or
- 27 kg/m² or higher, but below 30, with at least one weight-related health condition, such as high blood pressure, obstructive sleep apnoea or type 2 diabetes.
Meeting a BMI threshold does not automatically make the medicine suitable. A clinician must also assess medical history, current medicines, potential risks and the support needed during treatment. Wanting to lose a few kilograms for an event is not, by itself, a medical indication.
What should you discuss before starting?
Bring a complete list of medicines and supplements, along with details of previous weight-management treatment. In particular, mention:
- Previous pancreatitis, gallbladder problems, kidney disease or severe digestive symptoms.
- Gastroparesis, a condition in which the stomach empties unusually slowly.
- Diabetes treatment, episodes of low blood sugar or diabetic eye disease.
- Pregnancy, plans to become pregnant, or breastfeeding.
- Any planned operation or procedure involving general anaesthesia or deep sedation.
Tirzepatide should not be used during pregnancy. The EU product information advises stopping it at least one month before a planned pregnancy; arrange this with your prescriber. Discuss contraception before starting, and contact the prescriber promptly if pregnancy occurs. Breastfeeding requires an individual decision that considers the medicine and your nutritional needs.
Tell the anaesthesia team about treatment well before a planned procedure. Delayed stomach emptying can affect their assessment of aspiration risk. The surgical and prescribing teams should give you specific instructions; do not make up a stopping schedule yourself.
How much weight might you lose?
Clinical trial results show what happened to groups of participants under defined conditions. They cannot predict one person’s result.
In the SURMOUNT-1 trial, 2,539 adults with obesity or overweight and a weight-related complication, but without diabetes, were studied over 72 weeks. Average weight reductions were approximately 15% to 21% across the tirzepatide dose groups, compared with about 3% with placebo. Participants also received lifestyle support, and Eli Lilly funded the trial.
Those figures describe averages over 72 weeks, not short-term targets or guaranteed individual results. Treatment response, tolerability and the ability to continue treatment all matter. Early appetite changes and longer-term weight change should be assessed separately.
Why nutrition, strength and follow-up still matter
A lower number on the scales does not describe every change in the body. A body-composition substudy of SURMOUNT-1 found reductions in both fat mass and lean mass. Lean mass includes more than skeletal muscle, so the findings should not be described as a direct measurement of muscle loss alone.
Follow-up should assess whether you are eating adequately and maintaining everyday strength as well as losing weight. Discuss sufficient protein and activity suited to your health and ability, including strength training where appropriate. A falling weight alone does not show whether the overall plan is working well.
Useful review questions include whether you can eat and drink adequately, how you feel during everyday activities, and whether side effects are disrupting the routine. Progress should be assessed alongside tolerability and relevant health markers.
What happens when treatment stops?
Weight regain can occur after stopping. In SURMOUNT-4, participants first received tirzepatide during an initial treatment phase. Those subsequently switched to placebo regained substantial weight on average, while continued treatment helped maintain or extend the earlier reduction.
The study supports discussing maintenance before starting. It does not mean every patient needs the same treatment indefinitely. Ask what will happen if the medicine becomes unsuitable, difficult to tolerate or unaffordable, and how nutrition, activity and follow-up will continue.
What a medical weight-management plan should include
Medical weight management combines assessment, prescribed treatment where appropriate, nutrition and activity advice, and regular review. A tirzepatide programme should include instruction on how to give the injection and manage common problems, with dose changes guided by the prescriber.
Before committing, ask what your individual programme includes: medication costs, laboratory tests, follow-up appointments and access to advice about side effects. A displayed programme price does not establish that all of these are included.
Frequently asked questions
Are side effects unavoidable?
No. People differ in how they tolerate treatment. Having few symptoms does not mean the medicine is ineffective, and significant discomfort should not be treated as proof of success.
Can I increase the dose if my weight has stopped changing?
Do not increase it independently. Discuss the pattern with your prescriber, including appetite, food intake, activity, side effects and how long you have been on the current prescription. A plateau alone is not an instruction to take more medicine.
What should I do if nausea starts after a dose increase?
Tell your prescriber if it is troublesome, persistent or affecting your ability to eat and drink. Include when the dose changed and whether you are vomiting. Seek prompt care if you cannot keep fluids down, and immediate help for severe, persistent abdominal pain.
Can weight loss injections replace nutrition and exercise?
They are prescribed as part of a broader plan that includes nutrition, activity and medical follow-up. A medical consultation can clarify whether you meet the prescribing criteria, what support you would need and what ongoing treatment would cost.